Iovance Biotherapeutics (2LB) Stock Forecast & Price Target

Compare

18 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2LB Analyst Ratings

Moderate Buy

5 Buy

1 Hold

1 Sell

Based on 7 analysts giving stock ratings to

Iovance

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2LB Stock 12 Month Forecast

Average Price Target

€7.03

▲(222.64% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is €7.03 with a high forecast of €11.82 and a low forecast of €1.69. The average price target represents a 222.64% change from the last price of €2.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","3":"€3","6":"€6","9":"€9","12":"€12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.82103958,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€11.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.0335185501,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.68871994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.69</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.167,2.909618429230769,3.6522368584615386,4.394855287692307,5.137473716923077,5.880092146153846,6.622710575384615,7.3653290046153845,8.107947433846153,8.850565863076923,9.593184292307694,10.335802721538462,11.07842115076923,{"y":11.82103958,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.167,2.541347580776923,2.9156951615538462,3.290042742330769,3.664390323107692,4.038737903884615,4.413085484661538,4.787433065438462,5.161780646215385,5.536128226992307,5.910475807769231,6.284823388546154,6.6591709693230765,{"y":7.0335185501,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.167,2.130209226153846,2.093418452307692,2.0566276784615383,2.0198369046153846,1.9830461307692306,1.9462553569230767,1.909464583076923,1.872673809230769,1.8358830353846152,1.7990922615384615,1.7623014876923075,1.7255107138461536,{"y":1.68871994,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.986,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.963,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.012,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.133,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.507,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.968,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 77, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 86, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.002,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 87, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.167,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€11.82

Average Price Target€7.03

Lowest Price Target€1.69

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Pantginis

H.C. Wainwright

€7.58

Buy

247.92%

Upside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Akebia Therapeutics (NASDAQ: AKBA) and Denali Therapeutics (NASDAQ: DNLI)

Andrea Newkirk

Goldman Sachs

€1.26→€1.69

Sell

-22.68%

Downside

Reiterated

02/05/26

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

Etzer Darout

Barclays

€8.43

Buy

286.58%

Upside

Reiterated

02/04/26

Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

Tyler Van Buren

TD Cowen

€4.21

Buy

93.29%

Upside

Reiterated

01/29/26

TD Cowen Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

Yanan Zhu

Wells Fargo

€11.8

Buy

441.21%

Upside

Reiterated

01/16/26

Iovance Biotherapeutics (IOVA) Receives a Buy from Wells Fargo

Asthika Goonewardene

Truist Financial

Hold

―

Reiterated

12/05/25

Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (NASDAQ: MBX), Praxis Precision Medicines (NASDAQ: PRAX) and Iovance Biotherapeutics (NASDAQ: IOVA)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€8.43

Buy

286.58%

Upside

Reiterated

11/20/25

Mizuho Securities Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

Geulah Livshits

Chardan Capital

€14.33

Buy

557.18%

Upside

Reiterated

11/06/25

Updating our model for financials and the updated NSCLC data shifts our PT to $17.

Reni Benjamin

Citizens JMP

Hold

―

Reiterated

07/15/25

Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

David Dai

UBS

€1.69

Hold

-22.68%

Downside

Downgraded

05/16/25

Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges

Colleen M. Kusy

Robert W. Baird

€16.85→€2.53

Hold

15.97%

Upside

Downgraded

05/09/25

Baird downgrades Iovanace Biotherapeutics (IOVA) to NeutralBaird analyst Colleen Kusy downgraded Iovanace Biotherapeutics (NASDAQ: IOVA) from Outperform to Neutral with a price target of $3.00 (from $20.00).

Kelsey Goodwin

Piper Sandler

Hold

―

Reiterated

04/01/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Pantginis

H.C. Wainwright

€7.58

Buy

247.92%

Upside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Akebia Therapeutics (NASDAQ: AKBA) and Denali Therapeutics (NASDAQ: DNLI)

Andrea Newkirk

Goldman Sachs

€1.26→€1.69

Sell

-22.68%

Downside

Reiterated

02/05/26

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

Etzer Darout

Barclays

€8.43

Buy

286.58%

Upside

Reiterated

02/04/26

Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

Tyler Van Buren

TD Cowen

€4.21

Buy

93.29%

Upside

Reiterated

01/29/26

TD Cowen Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

Yanan Zhu

Wells Fargo

€11.8

Buy

441.21%

Upside

Reiterated

01/16/26

Iovance Biotherapeutics (IOVA) Receives a Buy from Wells Fargo

Asthika Goonewardene

Truist Financial

Hold

―

Reiterated

12/05/25

Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (NASDAQ: MBX), Praxis Precision Medicines (NASDAQ: PRAX) and Iovance Biotherapeutics (NASDAQ: IOVA)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€8.43

Buy

286.58%

Upside

Reiterated

11/20/25

Mizuho Securities Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

Geulah Livshits

Chardan Capital

€14.33

Buy

557.18%

Upside

Reiterated

11/06/25

Updating our model for financials and the updated NSCLC data shifts our PT to $17.

Reni Benjamin

Citizens JMP

Hold

―

Reiterated

07/15/25

Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

David Dai

UBS

€1.69

Hold

-22.68%

Downside

Downgraded

05/16/25

Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges

Colleen M. Kusy

Robert W. Baird

€16.85→€2.53

Hold

15.97%

Upside

Downgraded

05/09/25

Kelsey Goodwin

Piper Sandler

Hold

―

Reiterated

04/01/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

3 Months

xxx

Success Rate

10/13 ratings generated profit

Average Return

+4.42%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +4.42% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

8/13 ratings generated profit

Average Return

-4.02%

reiterated a buy rating 14 days ago

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of -4.02% per trade.

2 Years

xxx

Success Rate

8/13 ratings generated profit

Average Return

-2.54%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of -2.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2LB Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

100

In the current month, 2LB has received 11 Buy Ratings, 26 Hold Ratings, and 1 Sell Ratings. 2LB average Analyst price target in the past 3 months is 7.03.

Each month's total comprises the sum of three months' worth of ratings.

2LB Financial Forecast

2LB Earnings Forecast

Next quarter’s earnings estimate for 2LB is -€0.15 with a range of -€0.18 to -€0.11. The previous quarter’s EPS was -€0.21. 2LB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.

2LB Sales Forecast

Next quarter’s sales forecast for 2LB is €68.43M with a range of €62.97M to €79.08M. The previous quarter’s sales results were €57.20M. 2LB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.

2LB Stock Forecast FAQ

What is DE:2LB’s average 12-month price target, according to analysts?

Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is 7.03.

What is DE:2LB’s upside potential, based on the analysts’ average price target?

Iovance Biotherapeutics Inc has 222.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Iovance Biotherapeutics Inc a Buy, Sell or Hold?

Iovance Biotherapeutics Inc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 1 hold ratings and 1 sell ratings.

What is Iovance Biotherapeutics Inc’s share price target?

The average share price target for Iovance Biotherapeutics Inc is 7.03. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €11.82 ,and the lowest forecast is €1.69. The average share price target represents 222.64% Increase from the current price of €2.18.

What do analysts say about Iovance Biotherapeutics Inc?

Iovance Biotherapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Iovance Biotherapeutics Inc?

To buy shares of DE:2LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Iovance Biotherapeutics (2LB) Stock Forecast & Price Target

2LB Analyst Ratings

2LB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Iovance Biotherapeutics

2LB Analyst Recommendation Trends

2LB Financial Forecast

2LB Earnings Forecast

2LB Sales Forecast

2LB Stock Forecast FAQ

Detailed List of Analyst Forecasts